TSX · Biotechnology · CAD
Resverlogix Corp. (RVX.TO) Stock Analysis
Resverlogix Corp. (RVX.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
RVX.TO Key Statistics
As of Oct 21, 2026Trading
- Open
- CA$0.08
- Previous Close
- CA$0.08
- 52-Week Range
- 0.08–0.15
- Volume
- 48.00K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.06
Valuation
- Market Cap
- CA$27.54M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.04
Financials (FY)
- Revenue (FY)
- CA$0.00
- Net Income (FY)
- −CA$7.77M
- Shares Outstanding
- 344.29M
- 1-Year Return
- −27.27%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 25.55K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, RVX.TO closed at CA$0.08, −27.27% over 1 year.
Resverlogix Corp. (RVX.TO) has a market capitalization of CA$27.54M.
In fiscal 2025, RVX.TO reported revenue of CA$0.00.
RVX.TO Stock Return by Calendar Year
Resverlogix Corp. (RVX.TO) 10-year return: what CA$10,000 became
- 1 year
- CA$10,000 CA$7,273
- −27.27%
- 5 years
- CA$10,000 CA$1,509
- −84.91%
- 10 years
- CA$10,000 CA$392
- −96.08%
If you had invested CA$10,000 in Resverlogix Corp. (RVX.TO) 10 years ago, at the close on October 21, 2016, it would have been worth CA$392 at the close on October 21, 2026: −96.08% in total, −27.67% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −20.00% |
| 2025 | +66.67% |
| 2024 | −14.29% |
| 2023 | −50.00% |
| 2022 | −72.55% |
| 2021 | −45.74% |
| 2020 | −23.58% |
| 2019 | −62.61% |
| 2018 | +60.49% |
| 2017 | +20.59% |
| 2016 (partial year) | +45.30% |
As of October 21, 2026.
RVX.TO Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | CA$0.00 | −CA$7.77M | — |
| 2024 | CA$0.00 | −CA$7.64M | — |
| 2023 | CA$0.00 | −CA$16.74M | — |
| 2022 | CA$0.00 | −CA$3.61M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | CA$0.00 | — | −CA$5.06M | −CA$7.77M | — |
| 2024 | CA$0.00 | — | −CA$4.60M | −CA$7.64M | — |
| 2023 | CA$0.00 | — | −CA$6.21M | −CA$16.74M | — |
| 2022 | CA$0.00 | — | −CA$12.71M | −CA$3.61M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B